A formal analysis of cytokine networks in chronic fatigue syndrome.
Chronic Fatigue Syndrome (CFS) is a complex illness affecting 4 million Americans for which no characteristic lesion has been identified. Instead of searching for a deficiency in any single marker, we propose that CFS is associated with a profound imbalance in the regulation of immune function forcing a departure from standard pre-programmed responses. To identify these imbalances we apply network analysis to the co-expression of 16 cytokines in CFS subjects and healthy controls. Concentrations of IL-1a, 1b, 2, 4, 5, 6, 8, 10, 12, 13, 15, 17 and 23, IFN-γ, lymphotoxin-α (LT-α) and TNF-α were measured in the plasma of 40 female CFS and 59 case-matched controls. Cytokine co-expression networks were constructed from the pair-wise mutual information (MI) patterns found within each subject group. These networks differed in topology significantly more than expected by chance with the CFS network being more hub-like in design. Analysis of local modularity isolated statistically distinct cytokine communities recognizable as pre-programmed immune functional components. These showed highly attenuated Th1 and Th17 immune responses in CFS. High Th2 marker expression but weak interaction patterns pointed to an established Th2 inflammatory milieu. Similarly, altered associations in CFS provided indirect evidence of diminished NK cell responsiveness to IL-12 and LT-α stimulus. These observations are consistent with several processes active in latent viral infection and would not have been uncovered by assessing marker expression alone. Furthermore this analysis identifies key sub-networks such as IL-2:IFN-γ:TNF-α that might be targeted in restoring normal immune function.
Broderick
Gordon
G
Division of Pulmonary Medicine, Department of Medicine, University of Alberta, College Plaza, 8215 112 Street NW, Edmonton, Alberta, Canada. gordon.broderick@ualberta.ca
Fuite
Jim
J
Kreitz
Andrea
A
Vernon
Suzanne D
SD
Klimas
Nancy
N
Fletcher
Mary Ann
MA
D000328:Adult; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D015673:Fatigue Syndrome, Chronic / Q000097:blood / Q000276:immunology*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood*; D007378:Interleukins / Q000097:blood*; D007694:Killer Cells, Natural / Q000276:immunology; D008233:Lymphotoxin-alpha / Q000097:blood; D008875:Middle Aged; D018448:Models, Immunological; D015398:Signal Transduction / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D058504:Th17 Cells / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
D015415:Biomarkers; D016207:Cytokines; D007378:Interleukins; D008233:Lymphotoxin-alpha; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma
J Clin Immunol. 1993 Jan;13(1):30-40
8095270
Pac Symp Biocomput. 2000;:418-29
10902190
Nature. 1985 Dec 19-1986 Jan 1;318(6047):665-7
3001529
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7821-6
12060727
Haematologica. 2002 Apr;87(4):434-42
11940489
J Med Virol. 2001 Jun;64(2):141-8
11360246
Cost Eff Resour Alloc. 2004 Jun 21;2(1):4
15210053
Disabil Rehabil. 2008;30(16):1185-91
17852256
Nat Protoc. 2006;1(2):662-71
17406294
Clin Exp Rheumatol. 2006 Mar-Apr;24(2):179-82
16762155
Psychoneuroendocrinology. 2005 Feb;30(2):188-98
15471616
N Engl J Med. 2007 Jul 26;357(4):404-7
17652657
Pharmacogenomics. 2006 Apr;7(3):421-8
16610952
Blood. 2000 May 15;95(10):3183-90
10807786
Phys Rev E Stat Nonlin Soft Matter Phys. 2006 Sep;74(3 Pt 2):036104
17025705
Clin Exp Immunol. 2001 Oct;126(1):101-10
11678905
BMC Bioinformatics. 2006 Mar 20;7 Suppl 1:S7
16723010
J Clin Pathol. 2008 Jun;61(6):730-9
18057078
J Infect Dis. 2008 Apr 15;197(8):1171-84
18462164
J Psychosom Res. 2006 Jun;60(6):559-66
16731230
Brain Behav Immun. 2007 Nov;21(8):1063-74
17544255
Popul Health Metr. 2007 Jun 08;5:5
17559660
Clin Exp Immunol. 2005 Dec;142(3):505-11
16297163
J Psychiatr Res. 1997 Jan-Feb;31(1):149-56
9201656
J Immunol. 2009 Feb 15;182(4):2511-7
19201907
Oncogene. 2008 Jul 10;27(30):4150-60
18362887
Nat Immunol. 2007 Dec;8(12):1390-7
17994024
Eur J Immunol. 2008 Jul;38(7):1807-13
18506885
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8577-82
16723398
Ann Intern Med. 1994 Dec 15;121(12):953-9
7978722
BMC Health Serv Res. 2003 Dec 31;3(1):25
14702202
Phys Rev E Stat Nonlin Soft Matter Phys. 2004 Feb;69(2 Pt 2):026113
14995526
J Biol Chem. 2003 Jan 17;278(3):1910-4
12417590
J Allergy Clin Immunol. 2009 May;123(5):1004-11
19410689
Clin Exp Immunol. 2004 Feb;135(2):294-302
14738459
Clin Infect Dis. 1994 Jan;18 Suppl 1:S154-6
8148444
Cancer Res. 1990 Aug 15;50(16):5072-6
1696166
Cancer Sci. 2010 Jan;101(1):29-35
19886912
Behav Brain Funct. 2008 Sep 26;4:44
18822143
Genomics. 2008 Dec;92(6):393-9
18775774
Neuroimmunomodulation. 2002-2003;10(3):134-41
12481153
Lancet. 2006 Jan 28;367(9507):346-55
16443043
Wien Med Wochenschr. 1994;144(16):399-406
7856214
J Clin Microbiol. 1990 Jun;28(6):1403-10
2166084
J Transl Med. 2009 Nov 12;7:96
19909538
Nat Rev Neurosci. 2008 Jan;9(1):46-56
18073775
Immunity. 2007 Mar;26(3):371-81
17363300
Cell Immunol. 1997 May 25;178(1):42-52
9184697
Blood. 2009 Jul 2;114(1):109-18
19417211
J Immunol. 2009 Mar 1;182(5):2808-15
19234175
Immunol Rev. 2008 Dec;226:132-46
19161421
J Chem Inf Comput Sci. 2004 Nov-Dec;44(6):2145-56
15554685
Science. 2009 Oct 23;326(5952):585-9
19815723
Blood. 2003 Jul 1;102(1):207-14
12637316
J Comput Biol. 2007 Sep;14(7):961-72
17803373
J Pharm Biomed Anal. 2007 Jan 17;43(2):413-20
17000071
Pharmacogenomics. 2006 Apr;7(3):355-64
16610946
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18414-9
16339314
Appl Neuropsychol. 2001;8(1):51-64
11388124
Leukemia. 2003 Nov;17(11):2196-201
14523478
Dyn Med. 2008 Apr 08;7:6
18397528